Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK.
Rheumatology (Oxford). 2014 May;53(5):937-47. doi: 10.1093/rheumatology/ket463. Epub 2014 Jan 30.
The aims of this study were to examine the impact of peripheral joint OA across five large European countries and how people with OA use pharmacotherapies.
People with self-reported peripheral joint OA were selected from the 2011 five European countries (5EU) National Health and Wellness Survey (NHWS), which included 57 512 respondents from France, Germany, Italy, Spain and the UK. Information was recorded on symptoms, health status, health care utilization, work productivity and medication usage. All variables were analysed descriptively for the total population and individual countries.
A total of 3750 respondents met the inclusion criteria: 1635 (43.6%) UK, 961 (25.6%) France, 570 (15.2%) Germany, 316 (8.4%) Spain and 268 (7.1%) Italy. The majority were ages 55-74 years and most were overweight or obese. Health status [12-item Short Form version 2 (SF12v2)] was similar across all countries, with a mean (s.d.) of 40.53 (10.99); 21.5% self-reported experiencing depression. Most had visited a health care provider in the previous 6 months (n = 3537; 94.3%). One third were employed: 7% reported absenteeism and 24% presenteeism. The use of prescription medication for OA was reported by 46.9% of patients, over-the-counter (OTC) medication by 26.5%, and both by 9.4%. Medication use increased with pain severity. NSAIDs were the most commonly used medication. Opioid use varied from 1.8% in Italy to 54.5% in France. Fifty per cent reported full adherence (4-point Morisky Medication Adherence Scale), but only 30% reported satisfaction with their OA medication. Most used medication for half the days of the month.
Despite some wide variations in pharmacotherapy for OA treatment, the impact of OA on health status and work productivity is substantial and looks largely similar across major European countries.
本研究旨在考察五个欧洲大国外周关节 OA 的影响，以及 OA 患者如何使用药物治疗。
从 2011 年五个欧洲国家（5EU）国家健康和健康调查（NHWS）中选择了自我报告患有外周关节 OA 的患者，该调查包括来自法国、德国、意大利、西班牙和英国的 57512 名受访者。记录了症状、健康状况、医疗保健利用、工作生产力和药物使用情况。所有变量均针对总人群和个别国家进行了描述性分析。
共有 3750 名符合纳入标准的受访者：英国 1635 名（43.6%），法国 961 名（25.6%），德国 570 名（15.2%），西班牙 316 名（8.4%），意大利 268 名（7.1%）。大多数年龄在 55-74 岁之间，大多数超重或肥胖。所有国家的健康状况[12 项简短形式 2 版（SF12v2）]相似，平均（标准差）为 40.53（10.99）；21.5%的人自我报告患有抑郁症。大多数患者在过去 6 个月内看过医疗保健提供者（n=3537；94.3%）。三分之一的人有工作：7%报告缺勤，24%报告在职。36.9%的患者报告使用处方药治疗 OA，26.5%的患者报告使用非处方药，9.4%的患者报告同时使用两者。药物使用随着疼痛严重程度的增加而增加。非甾体抗炎药是最常用的药物。阿片类药物的使用从意大利的 1.8%到法国的 54.5%不等。50%的人报告完全遵守（4 点 Morisky 药物依从性量表），但只有 30%的人对 OA 药物的满意度。大多数人每月使用药物的天数为一半。
尽管 OA 治疗的药物治疗存在一些广泛差异，但 OA 对健康状况和工作生产力的影响是巨大的，并且在欧洲主要国家之间基本相似。
